Progression of organ manifestations upon enzyme replacement therapy in a patient with mucopolysaccharidosis type I/Hurler

World Journal of Pediatrics

Volumn 5, Issue 4, 2009, Pages 319-321

  Mercimek Mahmutoglu, Saadet ^a   Reilly, Christopher ^a   Human, Derek ^b   Waters, Paula J ^a   Stoeckler Ipsiroglu, Sylvia ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

^b Division of Cardiology   (Canada)

Author keywords

Hurler disease; Laronidase; Mucopolysaccharidosis type I

Indexed keywords

DIPHENHYDRAMINE; GLYCOSAMINOGLYCAN; IBUPROFEN; LARONIDASE; LEVO IDURONIDASE;

ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CHILD; CHILL; CLINICAL FEATURE; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE COURSE; ENZYME REPLACEMENT; FEMALE; GENE MUTATION; GLYCOSAMINOGLYCAN URINE LEVEL; HEARING LOSS; HOMOZYGOSITY; HUMAN; HURLER SYNDROME; HYDROCEPHALUS; KYPHOSIS; MISSENSE MUTATION; MITRAL VALVE DISEASE; MITRAL VALVE THICKENING; PHENOTYPE; PRESCHOOL CHILD; SHIVERING; TREATMENT DURATION; UMBILICAL HERNIA; URINARY EXCRETION; URINE LEVEL;

CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HEARING LOSS, SENSORINEURAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDURONIDASE; MALE; MUCOPOLYSACCHARIDOSIS I;

EID: 73349114336     PISSN: 17088569     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12519-009-0062-x     Document Type: Article

References (10)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. New York: McGraw-Hill, 2001: 3421-3452.
2. C. Peters M. Balthazor E.G. Shapiro R.J. King C. Kollman J.D. Hegland, et al. 1996 Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome Blood 87 4894 4902 1:CAS:528:DyaK28Xjt1Cksbs%3D 8639864 (Pubitemid 26162394)
3. J.E. Wraith L.A. Clarke M. Beck E.H. Kolodny G.M. Pastores J. Muenzer, et al. 2004 Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) J Pediatr 144 581 588 10.1016/j.jpeds.2004.01. 046 1:CAS:528:DC%2BD2cXjs1Wnsbg%3D 15126990 (Pubitemid 38594757)
4. S.S. Grewal R. Wynn J.E. Abdenur B.K. Burton M. Gharib C. Haase, et al. 2005 Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome Genet Med 7 143 146 1:CAS:528:DC%2BD2MXhtl2mtLs%3D 15714083
5. H.S. Scott T. Litjens P.V. Nelson D.A. Brooks J.J. Hopwood C.P. Morris 1992 alpha-L-iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype Hum Mutat 1 333 339 10.1002/humu.1380010412 1:CAS:528:DyaK3sXhsVGis7w%3D 1301941
6. M. Sifuentes R. Doroshow R. Hoft G. Mason I. Walot M. Diament, et al. 2007 A follow-up study of MPSI patients treated with laronidase enzyme replacement therapy for 6 years Mol Genet Metab 90 171 180 10.1016/j.ymgme.2006. 08.007 1:CAS:528:DC%2BD2sXnsl2kuw%3D%3D 17011223 (Pubitemid 46108607)
7. E.A. Braunlin J.M. Berry C.B. Whitley 2006 Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I Am J Cardiol 98 416 418 10.1016/j.amjcard.2006.02.047 1:CAS:528:DC%2BD28XntVWjtrw%3D 16860035 (Pubitemid 44062452)
8. V. Tokic I. Barisic N. Huzjak G. Petkovic K. Fumic E. Paschke 2007 Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I Eur J Pediatr 166 727 732 10.1007/s00431-006-0316-8 17043838 (Pubitemid 46800739)
9. J.A. Thomas S. Jacobs J. Kierstein J. Van Hove 2006 Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome J Inherit Metab Dis 29 762 10.1007/s10545-006-0457-y 1:STN:280: DC%2BD28nnvVagtQ%3D%3D 17089217
10. E.D. Kakkis J. Muenzer G.E. Tiller L. Waber J. Belmont M. Passage, et al. 2001 Enzyme-replacement therapy in mucopolysaccharidosis I N Engl J Med 344 182 188 10.1056/NEJM200101183440304 1:CAS:528:DC%2BD3MXosleksw%3D%3D 11172140 (Pubitemid 32064139)